Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, multi center evaluation of the Bioliumus A9 eluting Axxess stent system in de novo coronary artery lesions. The study outcome will measure reduction in major adverse cardiac events compared to a historial control group.

Next Previous
X
Search
Trial Profile

A prospective, multi center evaluation of the Bioliumus A9 eluting Axxess stent system in de novo coronary artery lesions. The study outcome will measure reduction in major adverse cardiac events compared to a historial control group.

Status: Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Umirolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms DIVERGE
  • Sponsors Devax

    • Most Recent Events

    • 23 May 2013 Long-term data were presented at EuroPCR 2013, according to a Biosensors International Group media release.
    • 30 May 2009 Results have been published in the March 23, 2009 issue of the Journal of the American College of Cardiology, according to a Devax media release.
    • 08 May 2009 New source identified and integrated (Australian New Zealand Clinical Trials Registry).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top